.. Mise-en-place-d-'un-plan-national-d-'alerte-sur-les-antibiotiques, 56 b) 58 c) Plan d'alerte sur les antibiotiques, pp.2011-2016

B. Indicateur-composite-de-bon-usage-des-antibiotiques and .. , 61 a) Score chiffré 62 b) Classe de performance et tendance évolutive, ., p.62

S. S. Tang, A. Apisarnthanarak, and L. Y. Hsu, « Mechanisms of ?-lactam antimicrobial resistance and epidemiology of major community-and healthcare-associated multidrugresistant bacteria, Adv. Drug Deliv. Rev, 2014.

P. Joly-guillou, M. Legrand, C. Nicolas-chanoine, M. Soussy, J. Wolf et al., Régnier, et Collégiale de Bactériologie-Virologie-Hygiène des Hôpitaux Universitaires de l'Ile de France, « Curbing methicillin-resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program, Arch. Intern. Med, vol.170, issue.6, pp.552-559, 2010.

D. Vodovar, G. Marcadé, L. Raskine, and I. Malissin, Ent??robact??ries productrices de b??ta-lactamases ?? spectre ??largi??: ??pid??miologie, facteurs de risque et mesures de pr??vention, La Revue de M??decine Interne, vol.34, issue.11, pp.687-693, 2013.
DOI : 10.1016/j.revmed.2012.10.365

. Invs, Réseau d'alerte,d'investigation et de surveillance des infections nosocomiales (Raisin), « Surveillance des bactéries multirésistantes dans les établissements de santé français, Réseau BMR-Raisin, vol.89269, issue.2, pp.6-2015, 326905.

«. Antibiotiques and ». , Disponible sur: http://www.scritub.com/limba, ANTIBIOTIQES- ANTIBACTERIENNES23541257.php. [Consulté le, pp.22-2015

D. M. Livermore and J. D. Williams, -Lactams: mode of action and mechanisms of bacterial resistance, Antibiotics in Lab-oratory Medicine, pp.502-78, 1996.
URL : https://hal.archives-ouvertes.fr/hal-00685796

N. Masuda, E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto et al., Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy, vol.44, issue.12, pp.12-3322, 2000.
DOI : 10.1128/AAC.44.12.3322-3327.2000

H. Nikaido, Antibiotic Resistance Caused by Gram???Negative Multidrug Efflux Pumps, Clinical Infectious Diseases, vol.27, issue.s1, pp.32-41, 1998.
DOI : 10.1086/514920

W. L. Veal, R. A. Nicholas, and W. M. Shafer, Overexpression of the MtrC-MtrD-MtrE Efflux Pump Due to an mtrR Mutation Is Required for Chromosomally Mediated Penicillin Resistance in Neisseria gonorrhoeae, Journal of Bacteriology, vol.184, issue.20, pp.20-5619, 2002.
DOI : 10.1128/JB.184.20.5619-5624.2002

F. Malouin and L. E. Bryan, Modification of penicillin-binding proteins as mechanisms of beta-lactam resistance., Antimicrobial Agents and Chemotherapy, vol.30, issue.1, pp.1-5, 1986.
DOI : 10.1128/AAC.30.1.1

J. P. Quinn, C. A. Divincenzo, D. A. Lucks, R. L. Luskin, K. L. Shatzer et al., Serious Infections Due to Penicillin-Resistant Strains of Viridans Streptococci with Altered Penicillin-Binding Proteins, Journal of Infectious Diseases, vol.157, issue.4, pp.764-769, 1988.
DOI : 10.1093/infdis/157.4.764

H. F. Chambers, Penicillin???Binding Protein???Mediated Resistance in Pneumococci and Staphylococci, The Journal of Infectious Diseases, vol.179, issue.s2, pp.353-359, 1999.
DOI : 10.1086/513854

K. Hiramatsu, Y. Katayama, H. Yuzawa, and E. T. Ito, Molecular genetics of methicillin-resistant Staphylococcus aureus, International Journal of Medical Microbiology, vol.292, issue.2, pp.67-74, 2002.
DOI : 10.1078/1438-4221-00192

R. Fontana, M. Aldegheri, M. Ligozzi, H. Lopez, A. Sucari et al., Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium., Antimicrobial Agents and Chemotherapy, vol.38, issue.9, pp.1980-1983, 1994.
DOI : 10.1128/AAC.38.9.1980

T. Rybkine, J. L. Mainardi, W. Sougakoff, E. Collatz, and E. L. Gutmann, Penicillin-Binding Protein 5 Sequence Alterations in Clinical Isolates of Enterococcus faecium with Different Levels of ??-Lactam Resistance, Journal of Infectious Diseases, vol.178, issue.1, pp.159-163, 1998.
DOI : 10.1086/515605

N. Datta and P. Kontomichalou, Penicillinase Synthesis Controlled By Infectious R Factors In Enterobacteriaceae, Nature, vol.87, issue.5007, pp.239-241, 1965.
DOI : 10.1021/ac60172a054

E. Ruppé, ??pid??miologie des b??ta-lactamases ?? spectre ??largi??: l???av??nement des CTX-M, Antibiotiques, vol.12, issue.1, pp.3-16, 2010.
DOI : 10.1016/j.antib.2010.01.003

J. D. Pitout and K. B. Laupland, Extended-spectrum ??-lactamase-producing Enterobacteriaceae: an emerging public-health concern, The Lancet Infectious Diseases, vol.8, issue.3, pp.159-166, 2008.
DOI : 10.1016/S1473-3099(08)70041-0

R. P. Ambler, « The structure of beta-lactamases », Philos, Trans. R. Soc. Lond. B. Biol

K. Bush, G. A. Jacoby, and E. A. Medeiros, A functional classification scheme for beta-lactamases and its correlation with molecular structure, Antimicrobial Agents and Chemotherapy, vol.39, issue.6, pp.1211-1233, 1995.
DOI : 10.1128/AAC.39.6.1211

D. L. Paterson and R. A. Bonomo, Extended-Spectrum Beta-Lactamases, Seminars in Respiratory and Critical Care Medicine, vol.24, issue.1, pp.657-686, 2005.
DOI : 10.1055/s-2003-37919

G. A. Jacoby and L. S. Munoz-price, The New ??-Lactamases, New England Journal of Medicine, vol.352, issue.4, pp.380-391, 2005.
DOI : 10.1056/NEJMra041359

J. D. Pitout, P. Nordmann, and K. B. Laupland, Emergence of Enterobacteriaceae producing extended-spectrum ??-lactamases (ESBLs) in the community, Journal of Antimicrobial Chemotherapy, vol.56, issue.1, pp.52-59, 2005.
DOI : 10.1093/jac/dki166

L. Poirel, T. Naas, and E. P. Nordmann, Genetic support of extended-spectrum betalactamases, Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis, vol.14, pp.75-81, 2008.

A. Philippon, R. Labia, and E. G. Jacoby, Extended-spectrum beta-lactamases., Antimicrobial Agents and Chemotherapy, vol.33, issue.8, pp.1131-1136, 1989.
DOI : 10.1128/AAC.33.8.1131

E. Centre, D. Prevention, C. , and «. Surveillance, Antimicrobial resistance surveillance in Europe 2013 -antimicrobial- resistance-surveillance-europe-2013.pdf ». [En ligne]. Disponible sur, pp.12-2015

P. Nordmann, Carbapenemase-producing Enterobacteriaceae: Overview of a major public health challenge, M??decine et Maladies Infectieuses, vol.44, issue.2, pp.51-56, 2014.
DOI : 10.1016/j.medmal.2013.11.007

P. Nordmann and A. Carrer, Les carbap??n??mases des ent??robact??ries, Les carbapénèmases des entérobactéries, pp.154-162, 2010.
DOI : 10.1016/S0929-693X(10)70918-0

H. Villegas, N. Wang, J. P. Woodford, and . Quinn, « Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases, Lancet Infect. Dis, vol.13, issue.9, pp.785-796, 2013.

M. Upadhyay, W. Warner, D. M. Welfare, E. N. Livermore, and . Woodford, « Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study, Lancet Infect. Dis, vol.10, issue.9, pp.597-602, 2010.

P. Nordmann, L. Poirel, T. R. Walsh, and D. M. Livermore, The emerging NDM carbapenemases, The emerging NDM carbapenemases, pp.588-595, 2011.
DOI : 10.1016/j.tim.2011.09.005

A. Paniara, M. Xanthaki, G. L. Toutouza, L. S. Daikos, and . Tzouvelekis, « Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey, J. Antimicrob. Chemother, vol.61, issue.1, pp.59-63, 2008.

G. Cornaglia and G. M. Rossolini, The emerging threat of acquired carbapenemases in Gram-negative bacteria, Clinical Microbiology and Infection, vol.16, issue.2, pp.99-101, 2010.
DOI : 10.1111/j.1469-0691.2009.03114.x

. Invs, Réseau d'alerte,d'investigation et de surveillance des infections nosocomiales (Raisin), « Entérobactéries productrices de carbapénèmases, EPC

. Disponible-sur, invs.sante.fr/Publications-et-outils/Rapports-et- syntheses/Maladies-infectieuses/2014/Consommation-d-antibiotiques-et-resistance-aux- antibiotiques-en-France-necessite-d-une-mobilisation-determinee-et-durable, Consulté le, pp.7-2015

E. J. Noreddin and . Karlowsky, Comparative review of the carbapenems, pp.1027-1052, 2007.

K. M. Papp-wallace, A. Endimiani, M. A. Taracila, and R. A. Bonomo, Carbapenems: Past, Present, and Future, Antimicrobial Agents and Chemotherapy, vol.55, issue.11, pp.4943-4960, 2011.
DOI : 10.1128/AAC.00296-11

M. L. Hammond and . Ertapenem, Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties, Journal of Antimicrobial Chemotherapy, vol.53, issue.suppl_2, pp.7-9, 2004.
DOI : 10.1093/jac/dkh203

D. Breilh, J. Texier-maugein, B. Allaouchiche, M. Saux, E. E. Boselli et al., Carbapenems, Journal of Chemotherapy, vol.237, issue.2, pp.1-17, 2013.
DOI : 10.1016/j.ijsu.2005.03.010

D. J. Mouton, D. J. Touw, A. M. Horrevorts, and A. A. Vinks, Comparative Pharmacokinetics of the Carbapenems, Comparative Pharmacokinetics of the Carbapenems, pp.185-201, 2012.
DOI : 10.2165/00003088-200039030-00002

A. Dalhoff, N. Janjic, and E. R. Echols, Redefining penems, Biochemical Pharmacology, vol.71, issue.7, pp.1085-1095, 2006.
DOI : 10.1016/j.bcp.2005.12.003

S. R. Norrby, P. A. Newell, K. L. Faulkner, and E. W. Lesky, Safety profile of meropenem: International clinical experience based on the first 3125 patients treated with meropenem, Journal of Antimicrobial Chemotherapy, vol.36, issue.suppl A, pp.207-223, 1995.
DOI : 10.1093/jac/36.suppl_A.207

K. Lakhal, B. Lortat-jacob, C. Neukirch, O. Pajot, and E. M. Wolff, Safe Use of Meropenem in a Patient with a Possible Nonimmediate Allergy to Imipenem, Pharmacotherapy, vol.57, issue.1, pp.1334-1338, 2007.
DOI : 10.1111/j.1398-9995.2004.00678.x

«. Plésiat, Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections, Antimicrob. Agents Chemother, vol.51, issue.10, pp.3531-3536, 2007.

L. Martínez-martínez, Extended-spectrum ??-lactamases and the permeability barrier, Clinical Microbiology and Infection, vol.14, pp.82-89, 2008.
DOI : 10.1111/j.1469-0691.2007.01860.x

S. E. Cosgrove, The Relationship between Antimicrobial Resistance and Patient Outcomes: Mortality, Length of Hospital Stay, and Health Care Costs, Clinical Infectious Diseases, vol.42, issue.Supplement 2
DOI : 10.1086/499406

M. Marín, C. Gudiol, C. Ardanuy, C. Garcia-vidal, L. Jimenez et al., Carratalà, « Factors influencing mortality In neutropenic patients with haematological malignancies or solid tumours with bloodstream infection

B. E. Murray, E. R. Rensimer, and H. L. Dupont, during Oral Administration of Trimethoprim or Trimethoprim-Sulfamethoxazole, New England Journal of Medicine, vol.306, issue.3, pp.130-135, 1982.
DOI : 10.1056/NEJM198201213060302

M. H. Prevot, A. Andremont, and H. Sancho-garnier, Epidemiology of intestinal colonization by members of the family Enterobacteriaceae resistant to cefotaxime in a hematology-oncology unit., Antimicrobial Agents and Chemotherapy, vol.30, issue.6, pp.945-947, 1986.
DOI : 10.1128/AAC.30.6.945

E. E. Bouvenot and . Eschwége, « Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae, JAMA, vol.279, issue.5, pp.365-370, 1998.

«. Quinn, Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use, JAMA, vol.289, issue.7, pp.885-888, 2003.

H. Goossens, M. Ferech, and R. Vander-stichele, Elseviers, « Outpatient antibiotic use in Europe and association with resistance: a cross-national database study », The Lancet, pp.9459-579, 2005.

L. Ministère-chargé-de and . Santé, « Plan national d'alerte sur les antibiotiques 2011-2016 ». [En ligne]. Disponible sur, pp.7-2015

«. Huovinen, The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance, N. Engl. J. Med, vol.337, issue.7, pp.441-446, 1997.

D. M. Livermore, Bacterial Resistance: Origins, Epidemiology, and Impact, Bacterial Resistance: Origins, Epidemiology, and Impact, pp.11-23, 2003.
DOI : 10.1086/344654

E. J. Gbikpi-benissan and . Cardinaud, Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria, Am. J. Respir. Crit. Care Med, vol.162, pp.837-843, 2000.

P. M. Lepper, E. Grusa, H. Reichl, and J. Högel, Consumption of Imipenem Correlates with ??-Lactam Resistance in Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy, vol.46, issue.9, pp.2920-2925, 2002.
DOI : 10.1128/AAC.46.9.2920-2925.2002

P. De-man, B. A. Verhoeven, H. A. Verbrugh, M. C. Vos, and J. N. Van-den-anker, An antibiotic policy to prevent emergence of resistant bacilli, The Lancet, vol.355, issue.9208, pp.9208-973, 2000.
DOI : 10.1016/S0140-6736(00)90015-1

H. Conseil-de-la-santé-publique, Rapport d'évaluation du plan pour préserver l'efficacité des antibiotiques, Disponible sur, pp.22-2015, 2007.

«. Ministère-chargé-de-la-santé and . Bulletin, Circulaire DHOS/E 2- DGS/SD5A n°2002-272 du 2 mai 2002 relative au bon usage des antibiotiques dans les établissements de santé et à la mise en place à titre expérimental de centres de conseil en antibiothérapie pour les médecins libéraux ». [En ligne]. Disponible sur, pp.22-2015

. Invs, Réseau d'alerte,d'investigation et de surveillance des infections nosocomiales (Raisin), « Enquête nationale de prévalence des infections nosocomiales et des traitements anti-infectieux en établissements de santé, p.2012, 2013.

«. Ministère-des-affaires-sociales-et-de-la-santé and . Instruction, 134 du 27 mars 2012 relative au bilan des activités de lutte contre les infections nosocomiales dans les établissement de santé pour l'année 2011 et modifiant son annexe 4 ». [En ligne]. Disponible sur, 286 du 16 juillet 2012 complétant la circulaire n°DGOS/PF2, pp.22-2015, 2012.

S. Boussat, S. Clement, S. Henard, and S. Rabaud, COL04-05 Retour sur l???utilisation pratique de l???outil ConsoRes ??? un pl??biscite ?? 3 ans du d??but d???un d??ploiement progressif, M??decine et Maladies Infectieuses, vol.44, issue.6, p.8, 2014.
DOI : 10.1016/S0399-077X(14)70058-7

S. Boussat, B. Demoré, A. Lozniewski, N. Aissa, and C. Rabaud, How to improve the collection and analysis of hospital antibiotic consumption: Preliminary results of the ConsoRes software experimental implementation, M??decine et Maladies Infectieuses, vol.42, issue.4, pp.154-160, 2012.
DOI : 10.1016/j.medmal.2012.02.006

P. Pavese, A. Bonadona, J. P. Vittoz, J. Labarère, L. Foroni et al., François, « Apport d'une consultation systématique d'infectiologie à la maîtrise de l'antibiothérapie en réanimation, pp.281-287, 2005.

G. Beaucaire, Am??liorer la prescription d'antibiotiques ?? l'h??pital??: comment??? Formation, organisation, ??valuation??: ??valuation et action, M??decine et Maladies Infectieuses, vol.33, pp.93-104, 2003.
DOI : 10.1016/S0399-077X(02)00443-2

F. Jary, J. Kaiser, T. Henon, J. Leroy, I. Patry et al., Appropriate use of carbapenems in the Besan??on university hospital, Appropriate use of carbapenems in the Besançon university hospital, pp.510-516, 2012.
DOI : 10.1016/j.medmal.2012.07.004

P. Roger, F. De-salvador, M. Schiano, E. Cua, S. Rancurel et al., « [Evaluation of clinical practice, medical computerized database and improvement of antibiotic therapy for acute community-acquired pneumonia] », Médecine Mal, Infect, vol.40, issue.7, pp.412-417, 2010.

. Gros, Impact of a multidisciplinary staff meeting on the quality of antibiotherapy prescription for bone and joint infections in orthopedic surgery, Médecine Mal. Infect, vol.42, issue.12, pp.603-607, 2012.